Purified anti-human CD31 Antibody

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 ?g per million cells in 100 ?l volume.?For ELISA Capture applications, a concentration of 1.0 ?g/mL is recommended. To obtain a linear standard curve, serial dilutions of CD31 recombinant protein ranging from 10 to 0.156 ng/mL is recommended for each ELISA plate. For immunocytochemistry, a concentration range of 2.5 - 10 μg/ml is recommended. It is recommended that the reagent be titrated for optimal performance for each application.

Clone WM59 has been reported to recognize the D2 extracellular portion of CD31.

Additional reported applications (for the relevant formats) include: immunofluorescence microscopy², immunohistochemical staining of acetone-fixed frozen tissue sections⁸,　blocking of platelet aggregation³, and spatial biology (IBEX)^11,12. Clone WM59 is not recommended for immunohistochemical staining of formalin-fixed paraffin-embedded sections. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 303143 & 303144).

The purified WM59 antibody is useful as a capture antibody for a sandwich ELISA assay, when used in conjunction with biotin anti-human CD31 antibody (Cat. No. 536604) antibody as the detection antibody.

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V Oxford University Press. New York.
2. Muczynski KA, et al. 2003. J. Am. Soc. Nephrol. 14:1336. (IF)
3. Wu XW, et al. 1997. Arterioscl. Throm. Vas. 17:3154. (Block)
4. Nagano M, et al. 2007. Blood 110:151. (FC) PubMed
5. MacFadyen JR, et al. 2005. FEBS Lett. 579:2569. PubMed
6. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
7. Sestak K, et al. 2007. Vet. Immunol. Immunopathol. 119:21.
8. Wicki A, et al. 2012. Clin. Cancer Res. 18:454. (FC, IHC) PubMed
9. Oeztuerk-Winder F, et al. 2012. EMBO J. 31:3431. (FC) PubMed
10. Bushway ME, et al. 2014. Biol Reprod. 90(5): 110 (IF) PubMed
11. Radtke AJ,　et al. 2020.　Proc Natl Acad Sci USA. 117:33455-33465. (SB)　PubMed
12. Radtke AJ,　et al. 2022.　Nat Protoc. 17:378-401. (SB)　PubMed

1. Xie T, et al. 2021. Sci Adv. 7: . PubMed
2. Robert J et al. 2017. eLife. 6 pii: e29595. PubMed
3. Bloodworth NC, et al. 2018. Circ Res. 123:e51. PubMed
4. Constantinescu-Bercu A, et al. 2020. eLife. 9:00. PubMed
5. Fitzgerald W, et al. 2018. Am J Reprod Immunol. 80:e12860. PubMed
6. Yoshihara S, et al. 2019. Front Immunol. 0.545833333. PubMed
7. Vukusic K, et al. 2019. Stem Cells Dev. 28:1078. PubMed
8. Olin A, et al. 2018. Cell. 174:1277. PubMed
9. Yoshitomi Y, et al. 2017. J Cell Sci. 130:916. PubMed
10. Nagano M, et al. 2007. Blood . 110:151. PubMed
11. Boulanger MD, et al. 2022. PLoS One. 17:e0269316. PubMed
12. Henrick BM, et al. 2021. Cell. . PubMed
13. Lundqvist A, et al. 2016. PLoS One. 11: 0161629. PubMed
14. Li X, et al. 2022. Cancer Cell Int. 22:157. PubMed
15. Mishra A, et al. 2021. Cell. 184(13):3394-3409.e20. PubMed
16. Evrard M et al. 2018. Immunity. 48(2):364-379 . PubMed
17. Lee SH, et al. 2022. Nat Commun. 13:5461. PubMed
18. Lakshmikanth T, et al. 2020. Cell Reports. 32(3):107923. PubMed
19. Kennedy-Darling J, et al. 2021. Eur J Immunol. 51:1262. PubMed
20. Fujiwara K, et al. 2020. Cancers (Basel). 12:. PubMed
21. Gunasekaran M, et al. 2018. J Immunol. 200:2535. PubMed
22. Ran LJ, et al. 2018. Mol Med Rep. 18:723. PubMed
23. Robert J, et al. 2017. Mol Neurodegener. 12:60. PubMed
24. Crawford LB, et al. 2021. J Virol. 95:. PubMed
25. Li H, et al. 2020. Haematologica. 105:1206. PubMed
26. Martin E, et al. 2020. JCI Insight. :5. PubMed

Monocytes, platelets, granulocytes, endothelial cells, lymphocyte subset

1. DeLisser H, et al. 1994. Immunol. Today 15:490.
2. Newman P, 1997. J. Clin. Invest. 99:3.
3. Fawcett J, et al. 1995. J. Cell Biol. 128:1229.